Want to join the conversation?
In 3Q15, $BWA's U.S. GAAP operating income was $237MM. Excluding the $9MM pretax impact of restructuring expense and the $4MM pretax impact of M&A expense, operating income was $250MM, or 13.3% of net sales, up from 12.5% in third quarter 2014.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.